593 related articles for article (PubMed ID: 26950094)
1. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma.
Bonilla X; Parmentier L; King B; Bezrukov F; Kaya G; Zoete V; Seplyarskiy VB; Sharpe HJ; McKee T; Letourneau A; Ribaux PG; Popadin K; Basset-Seguin N; Ben Chaabene R; Santoni FA; Andrianova MA; Guipponi M; Garieri M; Verdan C; Grosdemange K; Sumara O; Eilers M; Aifantis I; Michielin O; de Sauvage FJ; Antonarakis SE; Nikolaev SI
Nat Genet; 2016 Apr; 48(4):398-406. PubMed ID: 26950094
[TBL] [Abstract][Full Text] [Related]
2. Understanding the Molecular Genetics of Basal Cell Carcinoma.
Pellegrini C; Maturo MG; Di Nardo L; Ciciarelli V; Gutiérrez García-Rodrigo C; Fargnoli MC
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165358
[TBL] [Abstract][Full Text] [Related]
3. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
Danhof R; Lewis K; Brown M
Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802
[TBL] [Abstract][Full Text] [Related]
4. Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma.
Kuonen F; Huskey NE; Shankar G; Jaju P; Whitson RJ; Rieger KE; Atwood SX; Sarin KY; Oro AE
J Invest Dermatol; 2019 Jul; 139(7):1439-1448. PubMed ID: 30707899
[TBL] [Abstract][Full Text] [Related]
5. Smoothened variants explain the majority of drug resistance in basal cell carcinoma.
Atwood SX; Sarin KY; Whitson RJ; Li JR; Kim G; Rezaee M; Ally MS; Kim J; Yao C; Chang AL; Oro AE; Tang JY
Cancer Cell; 2015 Mar; 27(3):342-53. PubMed ID: 25759020
[TBL] [Abstract][Full Text] [Related]
6. Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma.
Yurchenko AA; Pop OT; Ighilahriz M; Padioleau I; Rajabi F; Sharpe HJ; Poulalhon N; Dreno B; Khammari A; Delord M; Alberti A; Soufir N; Battistella M; Mourah S; Bouquet F; Savina A; Besse A; Mendez-Lopez M; Grange F; Monestier S; Mortier L; Meyer N; Dutriaux C; Robert C; Saiag P; Herms F; Lambert J; de Sauvage FJ; Dumaz N; Flatz L; Basset-Seguin N; Nikolaev SI
Clin Cancer Res; 2022 Apr; 28(7):1422-1432. PubMed ID: 35078858
[TBL] [Abstract][Full Text] [Related]
7. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas.
Reifenberger J; Wolter M; Knobbe CB; Köhler B; Schönicke A; Scharwächter C; Kumar K; Blaschke B; Ruzicka T; Reifenberger G
Br J Dermatol; 2005 Jan; 152(1):43-51. PubMed ID: 15656799
[TBL] [Abstract][Full Text] [Related]
8. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
9. Molecular Variations in Histologic Subtypes of Basal Cell Carcinoma.
Deng M; Marsch AF; Petronic-Rosic V
Skinmed; 2017; 15(4):265-268. PubMed ID: 28859735
[TBL] [Abstract][Full Text] [Related]
10. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.
Sharpe HJ; Pau G; Dijkgraaf GJ; Basset-Seguin N; Modrusan Z; Januario T; Tsui V; Durham AB; Dlugosz AA; Haverty PM; Bourgon R; Tang JY; Sarin KY; Dirix L; Fisher DC; Rudin CM; Sofen H; Migden MR; Yauch RL; de Sauvage FJ
Cancer Cell; 2015 Mar; 27(3):327-41. PubMed ID: 25759019
[TBL] [Abstract][Full Text] [Related]
11. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.
Danial C; Sarin KY; Oro AE; Chang AL
Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616
[TBL] [Abstract][Full Text] [Related]
12. Hedgehog signaling in basal cell carcinoma.
Otsuka A; Levesque MP; Dummer R; Kabashima K
J Dermatol Sci; 2015 May; 78(2):95-100. PubMed ID: 25766766
[TBL] [Abstract][Full Text] [Related]
13. Tumor-Derived Suppressor of Fused Mutations Reveal Hedgehog Pathway Interactions.
Urman NM; Mirza A; Atwood SX; Whitson RJ; Sarin KY; Tang JY; Oro AE
PLoS One; 2016; 11(12):e0168031. PubMed ID: 28030567
[TBL] [Abstract][Full Text] [Related]
14. Targeting the hedgehog pathway to treat basal cell carcinoma.
Geeraert P; Williams JS; Brownell I
J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
[TBL] [Abstract][Full Text] [Related]
15. Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma.
Brinkhuizen T; Reinders MG; van Geel M; Hendriksen AJ; Paulussen AD; Winnepenninckx VJ; Keymeulen KB; Soetekouw PM; van Steensel MA; Mosterd K
J Am Acad Dermatol; 2014 Nov; 71(5):1005-8. PubMed ID: 25199678
[No Abstract] [Full Text] [Related]
16. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
17. Xanthomatous Dermal Changes in a Patient With Locally Advanced Basal Cell Carcinoma Treated Using Vismodegib.
Smith SDB; Clarke CN; Clark MA; Harker-Murray AK; Sokumbi O
Am J Dermatopathol; 2021 Aug; 43(8):585-587. PubMed ID: 33534208
[TBL] [Abstract][Full Text] [Related]
18. Hedgehog Pathway Inhibition.
Sekulic A; Von Hoff D
Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
[TBL] [Abstract][Full Text] [Related]
19. Clues to primary vismodegib resistance lie in histology and genetics.
Sun Q; Atzmony L; Zaki T; Peng A; Sugarman J; Choate KA
J Clin Pathol; 2020 Oct; 73(10):678-680. PubMed ID: 32217615
[TBL] [Abstract][Full Text] [Related]
20. Hedgehog Pathway Alterations Downstream of Patched-1 Are Common in Infundibulocystic Basal Cell Carcinoma.
Russell-Goldman E; MacConaill L; Hanna J
Am J Dermatopathol; 2021 Apr; 43(4):266-272. PubMed ID: 32796174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
